This Export Pharma Stock Rises 359% in 1 Year: Takeover Deal and Africa Growth Drive the Rally

This export pharma stock has turned Rs 1 lakh into roughly Rs 4.6 lakh in a single year. A drugmaker that sells most of its medicines in Africa returned 358.71% over the past 12 months, placing it among the top 31 performers on a screen of 195 NSE small-cap stocks dated 11 September 2026.

The company is Bliss GVS Pharma Ltd (NSE: BLISSGVS), a Mumbai-based maker of antimalarial, anti-infective and women's health medicines, best known in the market for its suppositories and pessaries. The Bliss GVS share price traded near Rs 706.70 around midday on 11 September 2026, up about 0.9% from the previous close of Rs 700.45, giving the company a market value of approximately Rs 7,482 crore.

Click Here – Get Free Investment Predictions

How Much Has This Export Pharma Stock Returned in 1 Year?

The short answer: approximately 359% in one year, from a close of Rs 152.70 on 10 September 2025 to Rs 700.45 on 10 September 2026. The export pharma stock touched a 52-week low of Rs 118 in November 2025 and a record high of Rs 725.90 on the NSE in early September 2026. That means the current price is about six times the low point of the year.

The table below shows how this export pharma stock has performed across time frames. The 1-year figure is close to close up to 10 September 2026; the other periods are simple price returns calculated to the 11 September 2026 midday price of Rs 706.70.

Period	Price Return (%)
1 Month	43.04%
6 Months	226.78%
1 Year	358.71%
3 Years	640.78%
5 Years	533.53%

This export pharma stock had no split or bonus issue during these windows, so the gains reflect real price appreciation. The 3-year return is higher than the 5-year return because the shares slipped to around Rs 66 in 2022 before recovering. Most of the wealth creation in this export pharma stock has happened since February 2026.

Why Did This Export Pharma Stock Rise So Sharply?

Three forces drove the move: a takeover by a larger chemicals company, a clear jump in profits, and a steady run of quality and expansion milestones in its core African markets. Each one added a new group of buyers to what had been a quiet, low-valuation export pharma stock for years.

1. Anupam Rasayan Takeover Deal

On 25 May 2026, Anupam Rasayan India agreed to buy a 43.30% stake in the company at Rs 299 per share, a deal worth approximately Rs 1,369.51 crore. The agreement triggered a mandatory open offer for another 26% of the expanded share capital, or 2,77,26,848 shares, at the same Rs 299 price, worth about Rs 829 crore.

The Bliss GVS share price hit its 20% upper circuit at Rs 381.10 on 26 May, the day after the announcement. For the buyer, this is its first entry into finished medicines, adding tablets, suppositories and other dosage forms to a business built on key starting materials. The export pharma stock had already rallied in February 2026 on media reports about a possible stake sale, which the company then called speculative.

2. Record Profits in FY26 and Q1 FY27

Earnings gave this export pharma stock a solid base. FY26 total income crossed Rs 1,000 crore for the first time, and net profit rose about 49% to Rs 134.73 crore from Rs 90.26 crore in FY25. Diluted EPS climbed to Rs 12 from Rs 7.95.

The June 2026 quarter was even stronger. Revenue from operations grew about 38% year on year to Rs 285.58 crore, and operating EBITDA nearly doubled to about Rs 76.4 crore, lifting the EBITDA margin to 26.75% from 19.92%. Net profit rose a smaller 16% to Rs 51.37 crore because other income fell and the tax rate normalised, but the core business showed its best quarter in years.

3. Africa Expansion and Quality Approvals

Africa contributes around 65% to 75% of revenue, and about 74% in the first nine months of FY26. Antimalarial products make up roughly one-third of sales, led by established brands sold through distributors the company has worked with for two decades. In January 2026, it set up a wholly owned subsidiary in the Democratic Republic of Congo.

In June 2026, its Palghar facility received WHO GMP compliance confirmation. A domestic rating agency also assigned an A- (Stable) long-term rating in April 2026, pointing to improved liquidity and lower receivable days. For an export pharma stock that once struggled with slow collections from African buyers, these were meaningful signals.

Why Is the Bliss GVS Share Price Far Above the Open Offer Price?

This export pharma stock trades at more than double the Rs 299 open offer price because the market is valuing the business on its future under a new owner, not on the deal price agreed in May. The open offer tendering window ran from 28 July to 10 August 2026, when the export pharma stock was already trading near Rs 465 to Rs 480.

Independent directors called the Rs 299 price fair and reasonable under takeover rules, since it was about 21% above the 60-day average price before the deal. But with the market price far higher, tendering at Rs 299 offered little appeal to most holders. The final tender outcome and completion of the main stake purchase could not be verified from the latest disclosures, and the June 2026 shareholding still showed the original promoters at 35.01%.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Export Pharma Stock Financials: Quarterly Performance

The table below shows five quarters of results for this export pharma stock on a consolidated basis. Total income includes other income, which was unusually high at about Rs 35 crore in the June 2025 quarter.

Quarter	Total Income (Rs Cr)	EBITDA (Rs Cr)	Net Profit (Rs Cr)	Net Margin (%)
Jun 2025	242.92	76.78	44.36	20.75
Sep 2025	252.86	51.93	28.59	11.15
Dec 2025	236.71	53.25	24.78	11.36
Mar 2026	268.15	55.60	37.00	13.84
Jun 2026	295.18	86.00	51.37	17.54

For this export pharma stock, profits dipped in the September and December 2025 quarters before recovering sharply. On an annual basis, net profit grew from Rs 23.13 crore in FY22 to Rs 134.73 crore in FY26, and operating cash flow reached Rs 138.72 crore in FY26. Debt to equity is only about 0.02, so the balance sheet is close to debt-free.

Export Pharma Stock Valuation: What Are You Paying Now?

Valuation has changed completely. At around Rs 707, the export pharma stock trades at a trailing PE of approximately 52.8 against an industry PE of about 38, and at roughly 6.3 times book value of Rs 112.19. Return on equity is about 10.8%, and the dividend yield is a thin 0.14%.

A year ago, this was an export pharma stock priced like a slow-growing exporter. Today the price assumes that profits keep growing at a fast pace under the new owner. That gap between current earnings and the market price is the central question for anyone looking at the Bliss GVS share now.

Shareholding: Who Owns This Export Pharma Stock?

The shareholding pattern of this export pharma stock shows an interesting shift. Foreign investors trimmed their holding while domestic institutions stepped in after the deal announcement.

Quarter	Promoters (%)	FII (%)	DII (%)	Public (%)
Jun 2025	35.44	12.65	6.54	45.36
Sep 2025	35.39	13.27	5.98	45.36
Dec 2025	35.36	14.54	5.78	44.32
Mar 2026	35.36	10.45	5.04	49.15
Jun 2026	35.01	8.07	9.47	47.45

DII holding nearly doubled to 9.47% in the June 2026 quarter, helped by new positions from two domestic alternative investment funds, while the state-run insurer cut its stake from 4.33% to 3.24%. FII holding fell from a peak of 14.54% to 8.07% as one large foreign holder cut its stake from 7.93% to 1.36% over the year. No mutual fund scheme holds a disclosed stake in this export pharma stock, which reflects its small size and limited liquidity.

Key Risks for This Export Pharma Stock

A 359% rally raises the stakes for new buyers. These are the main risks to track.

Valuation and Deal-Driven Pricing

Much of the rally is linked to the takeover story. If integration with the new owner is slow, or if the market decides the premium is excessive, the export pharma stock could lose a large part of its recent gains. The price is more than twice the level at which a well-informed buyer agreed to pay only four months ago.

Liquidity and Volatility Risk

This export pharma stock is a small-cap share with thin trading. Only about 1.09 lakh shares had changed hands on the NSE by midday on 11 September, and the stock has been locked in 5% upper and lower circuits several times in recent weeks, including a lower circuit on 4 September. Exiting a position quickly at a fair price may not always be possible in this export pharma stock.

Africa Concentration and Currency

With roughly three-quarters of revenue from Africa, the business is exposed to local currency swings, payment delays, regulatory changes and political instability. The company hedges only about 40% to 50% of its open foreign exchange exposure, and receivables have historically been high at around 190 to 200 days.

Leadership Changes

This export pharma stock has also seen several leadership changes at the top, including the exit of its managing director in November 2025 and a new CEO taking charge in July 2026. A change in control adds another layer of transition.

Download the Univest iOS App or Univest Android App to track the Bliss GVS share price live

Bliss GVS Share: Analyst View

The Bliss GVS share has moved from an overlooked exporter to a takeover-backed growth story within twelve months. The case for the export pharma stock rests on three pillars: rising margins, a strong position in African antimalarials, and a larger parent that can open doors to new products and markets. The case against it is valuation, deal uncertainty and thin liquidity.

Bliss GVS Share Price Target

No verified brokerage Bliss GVS share price target is publicly available right now, as this export pharma stock has limited formal research coverage. In the absence of a published Bliss GVS share price target, investors tend to watch price levels instead. The 52-week high of Rs 725.90 is the immediate resistance, while the Rs 600 to Rs 610 zone, where the stock hit its lower circuit in early September, is the nearest support to watch.

The Rs 299 open offer price is a reference for what the acquirer paid, not a floor for the Bliss GVS share price. Any future Bliss GVS share price target from a brokerage will likely depend on how quickly the new owner shares its growth plans and how the September and December quarter results compare with the strong June quarter.

Other Stocks to Track From the Same Return Screen

Beyond this export pharma stock, a screen of 195 small-cap NSE stocks dated 11 September 2026 also includes related names such as Acutaas Chemicals with a 1-year return of 136.67%, Shilpa Medicare at 125.18% and Garware Hi-Tech Films at 107.98%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this export pharma stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

This export pharma stock has delivered one of the biggest small-cap rallies of the past year, helped by a takeover by Anupam Rasayan, record FY26 profits and a sharp margin jump in the June 2026 quarter. The Bliss GVS share price now reflects high expectations, with a PE above 50 and a price more than twice the open offer level.

For long-term investors, the key signals are the progress of the change in control, growth in African markets and whether quarterly margins stay near the 26% level. For short-term traders, the 5% price band and thin volumes make position sizing and stop losses essential. Anyone considering this export pharma stock should treat it as a high-risk small-cap bet and size positions accordingly.

Frequently Asked Questions

Which export pharma stock rose 359% in 1 year?

Ans. Bliss GVS Pharma (NSE: BLISSGVS) is the export pharma stock that gained approximately 358.71% over one year, based on closing prices of 10 September 2025 and 10 September 2026. It was among the top 31 performers on a screen of 195 NSE small-cap stocks dated 11 September 2026.

Why did the Bliss GVS share price rise so much?

Ans. The Bliss GVS share price rose on Anupam Rasayan's agreement to buy a 43.30% stake, record FY26 profit of Rs 134.73 crore and a strong June 2026 quarter. Africa expansion and a WHO GMP confirmation for its Palghar plant added support.

What is the Anupam Rasayan open offer price for Bliss GVS Pharma?

Ans. The open offer price is Rs 299 per share for up to 26% of the expanded share capital, worth about Rs 829 crore. The tendering period ran from 28 July to 10 August 2026, while the shares traded well above that price.

What were Bliss GVS Pharma Q1 FY27 results?

Ans. Revenue from operations rose about 38% year on year to Rs 285.58 crore, and the EBITDA margin expanded to 26.75% from 19.92%. Net profit of the export pharma stock grew 16% to Rs 51.37 crore due to lower other income and a normal tax rate.

What is the Bliss GVS share price target?

Ans. No verified brokerage target is currently available for this export pharma stock. Investors are watching the 52-week high of Rs 725.90 as resistance and the Rs 600 to Rs 610 area as near-term support.

How much of Bliss GVS Pharma's revenue comes from Africa?

Ans. Africa contributes roughly 65% to 75% of revenue for this export pharma stock, and about 74% in the first nine months of FY26. Antimalarial medicines account for around one-third of total sales.

Is Bliss GVS Pharma overvalued after the rally?

Ans. The export pharma stock trades at a trailing PE of about 52.8 against an industry PE near 38, and at about 6.3 times book value. That is a steep premium, so earnings must keep growing quickly to support the price.

What are the main risks in this export pharma stock?

Ans. Key risks include deal-linked valuation, thin liquidity with frequent 5% circuits, heavy dependence on Africa, currency swings and leadership changes. Investors should size positions carefully and consult a SEBI-registered advisor.